[Media Releases] [Hankyung Economy]Yong Zu Kim, CEO of LegoChem Bio, 'construct new drugs like lego blocks…IPO in the first half'

Title: Hankyung Economy– Yong Zu Kim, CEO of LegoChem Bio, 'construct new drugs like lego blocks…IPO in first half'

Publication: Hankyung Economy / Eun Jee Shim

Date: 10 January 2013

Summary

• CEO of LegoChem, Dr. Yong Zu Kim explained “ever since started working on antibiotics in 1983, I have been focusing solely on developing drugs. I founded a venture company because know-hows and research capability accumulated for past 20 years could not be wasted”

• LegoChem constructs a new drug by arranging different scaffolds, just like building a structure with ‘Lego blocks’. CEO Dr. Kim said “using our own technology ‘LegoChemistry’, approximately 20 differentiated mother nucleus structures are assembled to make candidate substances for antibiotics, oncology and other medicines.

• LegoChem signed 7 license-out and 1 resource supply contracts and recently signed another license-out contract worth a billion dollars with a global pharmaceutical company, AstraZeneca, for newly developed antibiotic candidate substance.

• LegoChem’s technological advancement brought desirable outcome on technology evaluation for IPO.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).